Discovery of 1-(phenylsulfonyl)-1H-indole-based multifunctional ligands targeting cholinesterases and 5-HT6 receptor with anti-aggregation properties against amyloid-beta and tau

التفاصيل البيبلوغرافية
العنوان: Discovery of 1-(phenylsulfonyl)-1H-indole-based multifunctional ligands targeting cholinesterases and 5-HT6 receptor with anti-aggregation properties against amyloid-beta and tau
المؤلفون: Xavier Brazzolotto, Izabella Góral, Anna Pasieka, Gniewomir Latacz, Anna Więckowska, Adam Bucki, Dawid Panek, Barbara Malawska, Marcin Kołaczkowski, Tomasz Wichur, Raimon Sabaté, Damijan Knez, Monika Głuch-Lutwin, Justyna Godyń, Ewelina Honkisz-Orzechowska, Stanislav Gobec, Agata Siwek
المصدر: European Journal of Medicinal Chemistry. 225:113783
بيانات النشر: Elsevier BV, 2021.
سنة النشر: 2021
مصطلحات موضوعية: Pharmacology, Indole test, cholinesterase inhibitors, biology, CYP3A4, β-amyloid, Chemistry, Amyloid beta, Organic Chemistry, General Medicine, Alzheimer's disease, In vitro, Biochemistry, Tacrine, multifunctional agents, 5-HT6 antagonists, Drug Discovery, Tau protein, medicine, 5-HT6 receptor, biology.protein, Butyrylcholinesterase, medicine.drug, Cholinesterase
الوصف: Multifunctional ligands as an essential variant of polypharmacology are promising candidates for the treatment of multi-factorial diseases like Alzheimer's disease. Based on clinical evidence and following the paradigm of multifunctional ligands we have rationally designed and synthesized a series of compounds targeting processes involved in the development of the disease. The biological evaluation led to the discovery of two compounds with favorable pharmacological characteristics and ADMET profile. Compounds 17 and 35 are 5-HT6R antagonists (Ki = 13 nM and Ki = 15 nM respectively) and cholinesterase inhibitors with distinct mechanisms of enzyme inhibition. Compound 17, a tacrine derivative is a reversible inhibitor of acetyl- and butyrylcholinesterase (IC50 = 8 nM and IC50 = 24 nM respectively), while compound 35 with rivastigmine-derived phenyl N‐ethyl‐N‐methylcarbamate fragment is a selective, pseudo-irreversible inhibitor of butyrylcholinesterase (IC50 = 455 nM). Both compounds inhibit aggregation of amyloid β in vitro (75% for compound 17 and 68% for 35 at 10 μM) moreover, compound 35 is a potent tau aggregation inhibitor in cellulo (79%). In ADMET in vitro studies both compounds showed acceptable metabolic stability on mouse liver microsomes (28% and 60% for compound 17 and 35 respectively), no or little effect on CYP3A4 and 2D6 up to a concentration of 10 μM and lack of toxicity on HepG2 cell line (IC50 values of 80 and 21 μM, for 17 and 35 respectively). Based on the pharmacological characteristics and favorable pharmacokinetic properties, we propose compounds 17 and 35 as an excellent starting point for further optimization and in-depth biological studies.
تدمد: 0223-5234
DOI: 10.1016/j.ejmech.2021.113783
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05e6511bad0aaf428df90277374a636a
https://doi.org/10.1016/j.ejmech.2021.113783
Rights: OPEN
رقم الانضمام: edsair.doi.dedup.....05e6511bad0aaf428df90277374a636a
قاعدة البيانات: OpenAIRE
الوصف
تدمد:02235234
DOI:10.1016/j.ejmech.2021.113783